Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Blue dots signify proteins with statistically significant differences between the two groups and higher expression values in the PAS group (up-regulated), while green dots denote proteins with statistically significant differences between the two groups and higher expression values in the control group (down-regulated).Up-regulated proteins between placenta accreta spectrum cases and control cases.Protein IDProtein nameGene namePAS meanPAS SDControl meanControl SDLogFCFDRP01859Immunoglobulin heavy constant gamma 2IGHG220.780.0918.950.231.83449< 0.001P23284Peptidyl-prolyl cis: trans isomerase BPPIB20.90.0718.540.282.36253< 0.001P29622KallistatinSERPINA420.460.0319.30.091.16218< 0.001P06312Immunoglobulin kappa variable 4 to 1IGKV4-122.730.0518.870.163.86195< 0.001P02538Keratin type II cytoskeletal 6AKRT6A20.890.2719.180.441.70913< 0.001P01619Immunoglobulin kappa variable 3 to 20IGKV3-2023.330.0418.690.374.63617< 0.001P10153Non-secretory ribonucleaseRNASE222.760.0718.550.844.21399< 0.001P26599Isoform 3 of Polypyrimidine tract-binding protein 1PTBP120.970.0718.890.272.08704< 0.001P17900Ganglioside GM2 activatorGM2A22.110.1519.220.62.89388< 0.001Q9NZT1Calmodulin-like protein 5CALML520.950.0519.220.521.72479< 0.001P08779Keratin. type I cytoskeletal 16KRT1625.10.0218.031.017.07055< 0.001E9PAV3Nascent polypeptide-associated complex subunit alpha. muscle-specific formNACA21.180.0816.980.44.19932< 0.001Q04695Keratin. type I cytoskeletal 17KRT1721.360.2717.780.563.58797< 0.001P98160Basement membrane-specific heparan sulfate proteoglycan core proteinHSPG222.890.1119.710.133.18294< 0.001P02533Keratin. type I cytoskeletal 14KRT1426.960.123.230.093.72985< 0.001P41222Prostaglandin-H2 D-isomerasePTGDS20.970.0618.480.582.48096< 0.001P04908Histone H2A type 1-B/EHIST1H2AB24.260.0721.610.172.64485< 0.001P35527Keratin. type I cytoskeletal 9KRT929.90.0527.390.12.51254< 0.001Q06830Peroxiredoxin-1PRDX120.150.1218.080.882.0771< 0.001P29401Isoform 2 of TransketolaseTKT20.30.2217.80.532.50552< 0.001P04259Keratin. type II cytoskeletal 6BKRT6B26.230.0623.520.182.71622< 0.001P13647Keratin. type II cytoskeletal 5KRT524.760.1422.730.082.03099< 0.001P62805Histone H4HIST1H4A26.070.0524.10.071.9727< 0.001P16402Histone H1.3HIST1H1D23.70.0220.040.693.6596< 0.001P35858Isoform 2 of Insulin-like growth factor-binding protein complex acid labile subunitIGFALS21.020.1118.690.252.3364< 0.001Q5QNW6Isoform 2 of Histone H2B type 2-FHIST2H2BF24.90.0221.950.152.95295< 0.001P80108Phosphatidylinositol-glycan-specific phospholipase DGPLD119.370.2217.821.251.54757< 0.001P6227740S ribosomal protein S13RPS1321.520.0219.130.382.39112< 0.001P01040Cystatin-ACSTA23.41021.160.072.25607< 0.001P08571Monocyte differentiation antigen CD14CD1420.650.0818.460.322.1884< 0.001P68104Elongation factor 1-alpha 1EEF1A121.440.1819.280.392.1654< 0.001P3005060S ribosomal protein L12RPL1222.730.0620.750.291.97376< 0.001Q5BKX8Caveolae-associated protein 4CAVIN425.040.0423.060.121.97532< 0.001P07996Thrombospondin-1THBS121.160.0818.890.412.26357< 0.001P04264Keratin. type II cytoskeletal 1KRT130.830.0329.190.071.63986< 0.001P02745Complement C1q subcomponent subunit AC1QA24.050.0522.560.171.49755< 0.001P81605Isoform 2 of DermcidinDCD24.150.122.930.111.22032< 0.001P0DOX5Immunoglobulin gamma-1 heavy chain24.210.0621.630.112.57977< 0.001P31151Protein S100-A7S100A723.460.0721.420.22.04286< 0.001P07900Isoform 2 of Heat shock protein HSP 90-alphaHSP90AA122.010.1120.460.141.54478< 0.001P04406Glyceraldehyde-3-phosphate dehydrogenaseGAPDH24.620.0722.90.091.71432< 0.001P29508Serpin B3SERPINB321.240.1319.510.311.72562< 0.001P13671Complement component C6C624.160.0823.410.210.751649< 0.001P31944Caspase-14CASP1421.670.1520.20.171.47087< 0.001Q9P2E2Kinesin-like protein KIF17KIF1721.310.219.870.311.4488< 0.001P62979Ubiquitin-40S ribosomal protein S27aRPS27A240.0722.730.091.26772< 0.001Q5D862Filaggrin-2FLG220.60.0919.450.231.15151< 0.001P13645Keratin. type I cytoskeletal 10KRT1030.560.0129.40.041.15254< 0.001Q00887Pregnancy-specific beta-1-glycoprotein 9PSG920.410.0719.220.291.19618< 0.001Q13162Peroxiredoxin-4PRDX421.70.0719.690.922.00611< 0.001P06702Protein S100-A9S100A925.830.0424.860.060.96675< 0.001A0A0B4J1X5Immunoglobulin heavy variable 3 to 74IGHV3-7422.810.0721.820.170.986614< 0.001A0A183Late cornified envelope protein 6ALCE6A17.50.4816.630.170.86783< 0.001P35908Keratin. type II cytoskeletal 2 epidermalKRT228.830.0727.880.150.947344< 0.001P01023Alpha-2-macroglobulinA2M30.970.0430.160.080.817748< 0.001Q02413Desmoglein-1DSG121.850.0520.990.120.852002< 0.001Q14376UDP-glucose 4-epimeraseGALE24.450.1723.640.090.819099< 0.001P32119Peroxiredoxin-2PRDX223.230.0922.190.111.03265< 0.001P01042Isoform LMW of Kininogen-1KNG127.180.0826.40.120.778082< 0.001P61626Lysozyme CLYZ22.830.0722.010.120.81999< 0.001P02655Apolipoprotein C-IIAPOC229.030.0628.240.110.794366< 0.001P05154Plasma serine protease inhibitorSERPINA521.770.0820.20.431.57285< 0.001P02765Alpha-2-HS-glycoproteinAHSG27.240.1426.530.160.709687< 0.001P02751Isoform 15 of FibronectinFN125.240.0324.620.050.621365< 0.001Q06033Inter-alpha-trypsin inhibitor heavy chain H3ITIH322.250.0321.270.860.978899< 0.001P19827Inter-alpha-trypsin inhibitor heavy chain H1ITIH126.380.0525.560.30.81678< 0.001PAS placenta accreta spectrum, SD standard deviation, FC fold change, FDR false discovery rate.Down-regulated proteins between placenta accreta spectrum cases and control cases.Protein IDProtein nameGene namePAS meanPAS SDControl meanControl SDLogFCFDRP32189Glycerol kinaseGK19.71.6321.530.44− 1.8282< 0.001P18428Lipopolysaccharide-binding proteinLBP20.420.1622.370.15− 1.9578< 0.001P02774Isoform 3 of Vitamin D-binding proteinGC29.340.07300.1− 0.65129< 0.001Q15848AdiponectinADIPOQ23.520.0824.150.1− 0.63696< 0.001P01704Immunoglobulin lambda variable 2 to 14IGLV2-1421.60.1322.260.1− 0.6587< 0.001O43866CD5 antigen-likeCD5L24.290.1725.050.07− 0.76158< 0.001A0A0C4DH72Immunoglobulin kappa variable 1 to 6IGKV1-621.090.2421.880.14− 0.79015< 0.001P00736Complement C1r subcomponentC1R20.750.1422.170.13− 1.42028< 0.001P22792Carboxypeptidase N subunit 2CPN222.820.4723.510.07− 0.69241< 0.001Q96KN2Beta-Ala-His dipeptidaseCNDP118.670.1619.480.14− 0.80517< 0.001Q8NG31Kinetochore scaffold 1KNL119.130.2719.930.03− 0.80089< 0.001Q13790Apolipoprotein FAPOF23.260.0824.240.15− 0.97758< 0.001P01599Immunoglobulin kappa variable 1 to 17IGKV1-1720.530.0622.120.06− 1.58419< 0.001P0DJI8Serum amyloid A-1 proteinSAA124.730.126.40.07− 1.67552< 0.001P02654Apolipoprotein C-IAPOC124.030.0426.440.04− 2.4085< 0.001P0DJI9Serum amyloid A-2 proteinSAA218.230.8622.970.14− 4.73552< 0.001P0C0L4Complement C4-AC4A18.51.0722.960.11− 4.46277< 0.001P61769Beta-2-microglobulinB2M18.40.0620.441.58− 2.03388< 0.001Q9NZN5Rho guanine nucleotide exchange factor 12ARHGEF1218.410.0820.130.14− 1.71546< 0.001PAS placenta accreta spectrum, SD standard deviation, FC Fold change, FDR false discovery rate.A hierarchical clustered heat map of the relative abundances of proteins in the study and control groups.

Source: Results. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

We enrolled all pregnant women diagnosed with PAS who delivered at the Department of Obstetrics and Gynecology, Inonu University Faculty of Medicine, between 01/04/2021 and 01/01/2023, meeting the following inclusion criteria: women aged 18 to 39 years, with singleton viable pregnancies, diagnosed with PAS, and delivering at our investigating hospital.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Determination of biomarker candidates for the placenta accreta spectrum by plasma proteomic analysis

Study design awaiting verification · Scientific Reports · 2024

Original publication title

Determination of biomarker candidates for the placenta accreta spectrum by plasma proteomic analysis

Rauf Melekoglu; Seyma Yasar; Cemil Colak; Murat Kasap; Umran Karabulut Dogan; Saim Yologlu; Ercan Yilmaz; Sherif Shazly

© The Author(s) 2024

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

Placenta accreta spectrum (PAS) presents a significant obstetric challenge, associated with considerable maternal and fetal-neonatal morbidity and mortality. Nevertheless, it is imperative to acknowledge that a noteworthy subset of PAS cases remains undetected until the time of delivery, thereby contributing to an augmented incidence of morbidity among the affected individuals. The delayed identification of PAS not only hinders timely intervention but also exacerbates the associated health risks for both the maternal and fetal outcomes. This underscores the urgency to innovate strategies for early PAS diagnosis.

In this study, we aimed to explore plasma proteins as potential diagnostic biomarkers for PAS. Integrated transcriptome and proteomic analyses were conducted to establish a novel diagnostic approach. A cohort of 15 pregnant women diagnosed with PAS and delivering at Inonu University Faculty of Medicine between 01/04/2021 and 01/01/2023, along with a matched control group of 15 pregnant women without PAS complications, were enrolled. Plasma protein identification utilized enzymatic digestion and liquid chromatography-tandem mass spectrometry techniques. Proteomic analysis identified 228 plasma proteins, of which 85 showed significant differences (P < 0.001) between PAS and control cases.

We refined this to a set of 20 proteins for model construction, resulting in a highly accurate classification model (96.9% accuracy). Notable associations were observed for proteins encoded by P01859 (Immunoglobulin heavy constant gamma 2), P02538 (Keratin type II cytoskeletal 6A), P29622 [Kallistatin (also known as Serpin A4)], P17900 (Ganglioside GM2 activator Calmodulin-like protein 5), and P01619 (Immunoglobulin kappa variable 3 to 20), with fold changes indicating their relevance in distinguishing PAS from control groups. In conclusion, our study has identified novel plasma proteins that could serve as potential biomarkers for early diagnosis of PAS in pregnant women.

Further research and validation in larger PAS cohorts are necessary to determine the clinical utility and reliability of these proteomic biomarkers for diagnosing PAS.

Authors’ abstract

Placenta accreta spectrum (PAS) presents a significant obstetric challenge, associated with considerable maternal and fetal-neonatal morbidity and mortality. Nevertheless, it is imperative to acknowledge that a noteworthy subset of PAS cases remains undetected until the time of delivery, thereby contributing to an augmented incidence of morbidity among the affected individuals. The delayed identification of PAS not only hinders timely intervention but also exacerbates the associated health risks for both the maternal and fetal outcomes. This underscores the urgency to innovate strategies for early PAS diagnosis.

In this study, we aimed to explore plasma proteins as potential diagnostic biomarkers for PAS. Integrated transcriptome and proteomic analyses were conducted to establish a novel diagnostic approach. A cohort of 15 pregnant women diagnosed with PAS and delivering at Inonu University Faculty of Medicine between 01/04/2021 and 01/01/2023, along with a matched control group of 15 pregnant women without PAS complications, were enrolled. Plasma protein identification utilized enzymatic digestion and liquid chromatography-tandem mass spectrometry techniques. Proteomic analysis identified 228 plasma proteins, of which 85 showed significant differences (P < 0.001) between PAS and control cases.

We refined this to a set of 20 proteins for model construction, resulting in a highly accurate classification model (96.9% accuracy). Notable associations were observed for proteins encoded by P01859 (Immunoglobulin heavy constant gamma 2), P02538 (Keratin type II cytoskeletal 6A), P29622 [Kallistatin (also known as Serpin A4)], P17900 (Ganglioside GM2 activator Calmodulin-like protein 5), and P01619 (Immunoglobulin kappa variable 3 to 20), with fold changes indicating their relevance in distinguishing PAS from control groups. In conclusion, our study has identified novel plasma proteins that could serve as potential biomarkers for early diagnosis of PAS in pregnant women.

Further research and validation in larger PAS cohorts are necessary to determine the clinical utility and reliability of these proteomic biomarkers for diagnosing PAS.

Publication and source details

Original title: Determination of biomarker candidates for the placenta accreta spectrum by plasma proteomic analysis

Rauf Melekoglu; Seyma Yasar; Cemil Colak; Murat Kasap; Umran Karabulut Dogan; Saim Yologlu; Ercan Yilmaz; Sherif Shazly

Scientific Reports · 2024

© The Author(s) 2024https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T13:12:12.929017+00:00

DOI: 10.1038/s41598-024-53324-5 · PMC10837117